As of 12 May 2020, 4,425,094 people have been infected with SARS-CoV-2 with deaths reaching 297,723.Doctors are desperately looking for an effective drug, and there have been a number of candidates on trial; one of them, remdesivir, is probably the most exciting of all. This is the drug developed for the Ebola epidemic in 2015, but it was found to be less effective in clinical trials than in in vitro studies. Is remdesivir the panacea for COVID-19?
The signatories of this Joint Statement are a group of health professional societies, non-profit organizations, advocates, policymakers and citizens. We hold the strong position that the global fight against Covid–19 will be won only if all stakeholders play their part. Therefore, we urge all global diagnostics, pharmaceutical and vaccine companies, including Gilead, to meet the following recommendations to ensure that all of humanity will have people’s vaccines, people’s medicines and people’s diagnostics.
As the coronavirus pandemic claims lives and overwhelms health care systems throughout the world, scientists are closely watching several late-stage trials of the antiviral drug remdesivir. Developed to treat Ebola, remdesivir is now being tested against COVID-19.